FDA Inspection
Abraxis Bioscience, LLCAbraxis Bioscience, LLC – FDA Inspection, Apr 6, 2022
Record Details
This FDA Inspection record concerns Abraxis Bioscience, LLC, with an inspection on April 6, 2022, issued by the Center for Drug Evaluation and Research, covering drugs.
- Company
- Abraxis Bioscience, LLC
- Inspection Date
- April 6, 2022
- Product Type
- Drugs
View Company Profile
ID · 17dedab2-0d44-4c20-8a3a-2b3820d76f39
Inspection Facts
Official Action Indicated (OAI)
Significant objectionable conditions were found and regulatory or administrative action is recommended.
- Inspection number
- 1166508
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
FDA Citations
2- 21 CFR 211.113(b)Procedures for sterile drug products
- 21 CFR 211.192Investigations of discrepancies, failures
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Abraxis Bioscience, LLC
9| Date | Classification | Office | Project area |
|---|---|---|---|
| October 6, 2023 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| February 19, 2020 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| August 17, 2018 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| June 24, 2016 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| August 8, 2014 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Abraxis Bioscience, LLC
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.